Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an IL-2 receptor agonist. Patients saw improvements in EASI, vIGA-AD and Itch NRS scores.
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended ...
Kymera Therapeutics has commenced dosing in its BROADEN2 Phase IIb clinical trial assessing oral signal transducer and activator of transcription 6 (STAT6) degrader, KT-621, in moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results